Product InnovationThe jointly developed GLP-2 oral candidate could provide substantially greater convenience and dose-titration fine control, which would offer significant advantages to a currently-underserved patient population suffering from a severe, debilitating, chronic condition.
Regulatory DevelopmentsThe FDA agreed to Entera Bio's proposal that the New Drug Application for its lead candidate EB613 would be supported by a single multinational, randomized, double-blind, placebo-controlled, 24-month Phase 3 study in women with post-menopausal osteoporosis.